Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches

Sumitomo Pharma President Hiroshi Nomura Sumitomo Pharma is expected to miss its revenue and profit targets under its mid-term business plan for FY2018-FY2022, with forecasts for the final year released on May 13 falling below the goals on both fronts...read more